|
Study | Aim of the study or primary endpoint | SCD | Mean daily dose of ARB | Results |
|
ELITE II [14] | Losartan versus captopril to improve survival in patients with NYHA II–IV and FE ≤ 40% | Secondary endpoint | Losartan 50 mg versus captopril 50 mg t.i.d. | Losartan not superior for mortality Higher incidence of SCD or RCA with losartan | HR 1.25 CI 95% (0.98–1.60)
|
|
Val-HeFT [15] | Valsartan for mortality and morbidity in NYHA II–IV | | Valsartan 160 mg b.i.d. versus placebo | Total mortality similar in the two groups RCA improved with valsartan | RR 1.02 CI 97.5% (0.88–1.18) 0.6% versus 1.0% |
|
OPTIMAAL [16] | Losartan versus captopril to decrease all-cause mortality after acute MI | Secondary endpoint | Losartan 50 mg versus captopril 50 mg t.i.d. | Trend in favor of captopril (death from any cause) Higher incidence of SCD or RCA with losartan | RR 1.13 CI 95% (0.99–1.28)
RR 1.19; CI 95% 0·98–1·43; |
|
VALIANT [17] | Valsartan versus captopril in patients with MI associated with HF and/or LVD | | Valsartan 160 mg b.i.d. versus captopril 50 mg t.i.d. versus valsartan + captopril | Valsartan noninferior to captopril for total mortality | HR 1.00 CI 97.5% (0.90–1.1)
|
|
CHARM post hoc analysis [22] | Candesartan for cause-specific mortality in HF patients | — | Candesartan titrated to 32 mg versus placebo | Reduction of SCD with candesartan | HR 0.85 CI 95% (0.73–0.99)
|
|
HEAAL [32] | Losartan 50 mg versus 150 mg for death or admission for HF | — | Losartan 50 mg versus losartan 150 mg | Reduction of death or admission for HF with 150 mg No effects on mortality | HR 0.90, 95% CI 0.82–0.99; HR 0.94, 95% CI 0.84–1.04; |
|
COMPANION post-hoc analysis [26] | Predictors of SCD or ICD intervention in patients receiving CRT | — | Unknown | Both ACE-i and ARBs reduced the risk of appropriate shocks | ACE-i: HR 0.44 CI 95% (0.26–0.75)
ARBs: HR 0.53 CI 95% (0.28–0.996) P 0.05 |
|
Obeyesekere et al. [27] | Predictors of appropriate ICD interventions in a primary prevention population | — | Unknown | Absence of ACE-i/ARBs predicts appropriate ICD intervention | OR 0.06 CI 95% (0.01–0.37)
|
|
Francia et al. [28] | Predictors of appropriate ICD interventions in a primary prevention population | — | Losartan 50 mg (75% of patients) | Low-dose ARBs associated with higher risk of ICD intervention | HR 2.9 CI 95% (1.1–7)
|
|